Key Takeaways Sanofi will acquire BPMC for up to $9.5B, including a 27$149.4M and is projected to hit $2B by 2030. SNY aims to reduce Dupixent reliance by expanding its immunology portfolio through acquisitions.Sanofi (SNY) announced that it has entered into a definitive agreement to acquire Blueprint Medicines (BPMC) for a total deal value of up to$9.5 billion. Following the announcement, shares of BPMC are ...